Heron Therapeutics (NASDAQ:HRTX) Downgraded by Zacks Research to “Strong Sell”

Zacks Research lowered shares of Heron Therapeutics (NASDAQ:HRTX) from a hold rating to a strong sell rating in a report published on Monday morning,Zacks.com reports.

HRTX has been the topic of a number of other reports. Weiss Ratings reiterated a “sell (e+)” rating on shares of Heron Therapeutics in a research report on Tuesday, April 21st. HC Wainwright reiterated a “buy” rating and set a $6.00 target price on shares of Heron Therapeutics in a research report on Friday, January 9th. Three analysts have rated the stock with a Buy rating and two have given a Sell rating to the stock. According to MarketBeat, the stock presently has a consensus rating of “Hold” and a consensus target price of $4.50.

Heron Therapeutics Price Performance

NASDAQ:HRTX opened at $1.21 on Monday. The firm has a market cap of $228.25 million, a PE ratio of -9.31 and a beta of 1.42. Heron Therapeutics has a 12 month low of $0.74 and a 12 month high of $2.61. The company has a quick ratio of 1.51, a current ratio of 2.48 and a debt-to-equity ratio of 10.59. The company’s 50-day moving average price is $0.96 and its two-hundred day moving average price is $1.16.

Heron Therapeutics (NASDAQ:HRTX) last released its quarterly earnings results on Thursday, February 26th. The biotechnology company reported ($0.02) EPS for the quarter, beating analysts’ consensus estimates of ($0.03) by $0.01. The firm had revenue of $40.59 million during the quarter, compared to analyst estimates of $39.53 million. On average, equities analysts anticipate that Heron Therapeutics will post -0.05 EPS for the current fiscal year.

Institutional Investors Weigh In On Heron Therapeutics

Several large investors have recently bought and sold shares of the company. Apeiron RIA LLC increased its stake in Heron Therapeutics by 17.6% in the first quarter. Apeiron RIA LLC now owns 305,668 shares of the biotechnology company’s stock valued at $245,000 after purchasing an additional 45,700 shares in the last quarter. Redwood Family Wealth LLC bought a new stake in Heron Therapeutics in the fourth quarter valued at approximately $84,000. Caitong International Asset Management Co. Ltd increased its stake in Heron Therapeutics by 335.2% in the fourth quarter. Caitong International Asset Management Co. Ltd now owns 35,106 shares of the biotechnology company’s stock valued at $46,000 after purchasing an additional 27,040 shares in the last quarter. Invesco Ltd. increased its stake in Heron Therapeutics by 33.0% in the fourth quarter. Invesco Ltd. now owns 307,861 shares of the biotechnology company’s stock valued at $400,000 after purchasing an additional 76,466 shares in the last quarter. Finally, XTX Topco Ltd increased its stake in Heron Therapeutics by 687.6% in the fourth quarter. XTX Topco Ltd now owns 240,197 shares of the biotechnology company’s stock valued at $312,000 after purchasing an additional 209,700 shares in the last quarter. Institutional investors own 80.01% of the company’s stock.

Heron Therapeutics Company Profile

Heron Therapeutics, Inc is a commercial-stage biotechnology company focused on developing and commercializing therapies in pain management and supportive care for patients undergoing medical and surgical procedures. The company’s research is dedicated to addressing unmet needs in oncology supportive care and post-operative pain management through innovative drug formulations designed to improve patient outcomes and reduce reliance on opioids.

Heron’s first approved therapy, SUSTOL (granisetron) extended-release injection, received U.S.